These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 34679238)

  • 41. RON and MET Co-overexpression Are Significant Pathological Characteristics of Poor Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Triple-Negative Breast Cancer.
    Weng TH; Yao MY; Xu XM; Hu CY; Yao SH; Liu YZ; Wu ZG; Tang TM; Fu PF; Wang MH; Yao HP
    Cancer Res Treat; 2020 Jul; 52(3):973-986. PubMed ID: 32324988
    [TBL] [Abstract][Full Text] [Related]  

  • 42. AXL Controls Directed Migration of Mesenchymal Triple-Negative Breast Cancer Cells.
    Zajac O; Leclere R; Nicolas A; Meseure D; Marchiò C; Vincent-Salomon A; Roman-Roman S; Schoumacher M; Dubois T
    Cells; 2020 Jan; 9(1):. PubMed ID: 31963783
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer.
    He J; McLaughlin RP; van der Noord V; Foekens JA; Martens JWM; van Westen G; Zhang Y; van de Water B
    Breast Cancer Res Treat; 2019 Nov; 178(2):263-274. PubMed ID: 31388935
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Discovery of a potent and selective Axl inhibitor in preclinical model.
    Inoue S; Yamane Y; Tsukamoto S; Azuma H; Nagao S; Murai N; Nishibata K; Fukushima S; Ichikawa K; Nakagawa T; Hata Sugi N; Ito D; Kato Y; Goto A; Kakiuchi D; Ueno T; Matsui J; Matsushima T
    Bioorg Med Chem; 2021 Jun; 39():116137. PubMed ID: 33930844
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Axl receptor tyrosine kinase expression in breast cancer.
    D'Alfonso TM; Hannah J; Chen Z; Liu Y; Zhou P; Shin SJ
    J Clin Pathol; 2014 Aug; 67(8):690-6. PubMed ID: 24904064
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Metformin targets Axl and Tyro3 receptor tyrosine kinases to inhibit cell proliferation and overcome chemoresistance in ovarian cancer cells.
    Kim NY; Lee HY; Lee C
    Int J Oncol; 2015 Jul; 47(1):353-60. PubMed ID: 25975389
    [TBL] [Abstract][Full Text] [Related]  

  • 47. S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab.
    Burbridge MF; Bossard CJ; Saunier C; Fejes I; Bruno A; Léonce S; Ferry G; Da Violante G; Bouzom F; Cattan V; Jacquet-Bescond A; Comoglio PM; Lockhart BP; Boutin JA; Cordi A; Ortuno JC; Pierré A; Hickman JA; Cruzalegui FH; Depil S
    Mol Cancer Ther; 2013 Sep; 12(9):1749-62. PubMed ID: 23804704
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Structure-based optimization of 1H-imidazole-2-carboxamides as Axl kinase inhibitors utilizing a Mer mutant surrogate.
    Keung W; Boloor A; Brown J; Kiryanov A; Gangloff A; Lawson JD; Skene R; Hoffman I; Atienza J; Kahana J; De Jong R; Farrell P; Balakrishna D; Halkowycz P
    Bioorg Med Chem Lett; 2017 Feb; 27(4):1099-1104. PubMed ID: 28082036
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dual Inhibition of MEK and AXL Targets Tumor Cell Heterogeneity and Prevents Resistant Outgrowth Mediated by the Epithelial-to-Mesenchymal Transition in NSCLC.
    Konen JM; Rodriguez BL; Padhye A; Ochieng JK; Gibson L; Diao L; Fowlkes NW; Fradette JJ; Peng DH; Cardnell RJ; Kovacs JJ; Wang J; Byers LA; Gibbons DL
    Cancer Res; 2021 Mar; 81(5):1398-1412. PubMed ID: 33402388
    [TBL] [Abstract][Full Text] [Related]  

  • 50. AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers.
    Balaji K; Vijayaraghavan S; Diao L; Tong P; Fan Y; Carey JP; Bui TN; Warner S; Heymach JV; Hunt KK; Wang J; Byers LA; Keyomarsi K
    Mol Cancer Res; 2017 Jan; 15(1):45-58. PubMed ID: 27671334
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeting of the AXL receptor tyrosine kinase by small molecule inhibitor leads to AXL cell surface accumulation by impairing the ubiquitin-dependent receptor degradation.
    Lauter M; Weber A; Torka R
    Cell Commun Signal; 2019 Jun; 17(1):59. PubMed ID: 31171001
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Structure-Based Virtual Screening, Synthesis and Biological Evaluation of Potential FAK-FAT Domain Inhibitors for Treatment of Metastatic Cancer.
    Kandil SB; Jones SR; Smith S; Hiscox SE; Westwell AD
    Molecules; 2020 Jul; 25(15):. PubMed ID: 32751931
    [TBL] [Abstract][Full Text] [Related]  

  • 53. G protein-coupled KISS1 receptor is overexpressed in triple negative breast cancer and promotes drug resistance.
    Blake A; Dragan M; Tirona RG; Hardy DB; Brackstone M; Tuck AB; Babwah AV; Bhattacharya M
    Sci Rep; 2017 Apr; 7():46525. PubMed ID: 28422142
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Targeting AXL overcomes resistance to docetaxel therapy in advanced prostate cancer.
    Lin JZ; Wang ZJ; De W; Zheng M; Xu WZ; Wu HF; Armstrong A; Zhu JG
    Oncotarget; 2017 Jun; 8(25):41064-41077. PubMed ID: 28455956
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficient Arylation of 2,7-Naphthyridin-1(2
    Wang MS; Xu HC; Gong Y; Qu RY; Zhuo LS; Huang W
    ACS Comb Sci; 2020 Sep; 22(9):457-467. PubMed ID: 32589005
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inhibition of the Receptor Tyrosine Kinase AXL Restores Paclitaxel Chemosensitivity in Uterine Serous Cancer.
    Palisoul ML; Quinn JM; Schepers E; Hagemann IS; Guo L; Reger K; Hagemann AR; McCourt CK; Thaker PH; Powell MA; Mutch DG; Fuh KC
    Mol Cancer Ther; 2017 Dec; 16(12):2881-2891. PubMed ID: 28904132
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Axl receptor tyrosine kinase is up-regulated in metformin resistant prostate cancer cells.
    Bansal N; Mishra PJ; Stein M; DiPaola RS; Bertino JR
    Oncotarget; 2015 Jun; 6(17):15321-31. PubMed ID: 26036314
    [TBL] [Abstract][Full Text] [Related]  

  • 58. AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective.
    Myers SH; Brunton VG; Unciti-Broceta A
    J Med Chem; 2016 Apr; 59(8):3593-608. PubMed ID: 26555154
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Screening and identification of novel compounds with potential anti-proliferative effects on gallium-resistant lung cancer through an AXL kinase pathway.
    Oyewumi MO; Alazizi A; Liva S; Lin L; Geldenhuys WJ
    Bioorg Med Chem Lett; 2014 Sep; 24(18):4553-4556. PubMed ID: 25131538
    [TBL] [Abstract][Full Text] [Related]  

  • 60. MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation.
    Rho JK; Choi YJ; Kim SY; Kim TW; Choi EK; Yoon SJ; Park BM; Park E; Bae JH; Choi CM; Lee JC
    Cancer Res; 2014 Jan; 74(1):253-62. PubMed ID: 24165158
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.